Lilly Launches Novel Alzheimer's Treatment Lormalzi in India at Rs 91,688 per Vial

Eli Lilly Launches Groundbreaking Alzheimer's Therapy in India

Eli Lilly has launched its Alzheimer's drug Lormalzi (donanemab) in India, introducing a new class of therapies that target the underlying biology of the disease rather than just treating symptoms. The therapy has been approved for patients with early symptomatic Alzheimer's, including mild cognitive impairment and early dementia.

Donanemab works by clearing amyloid plaques—protein deposits in the brain widely believed to play a central role in cognitive decline. This once-monthly amyloid plaque-targeting therapy in India offers a dosing approach that can be adjusted based on how much plaque reduction is achieved during treatment. The 350 mg vial of Lormalzi is priced at Rs 91,688 in India.

Lilly is establishing an Alternate Access program to help expand access to donanemab in India for eligible patients. This disease-modifying therapy significantly slows cognitive and functional decline compared to placebo as demonstrated in clinical trials. Studies have shown up to 35% slowing of decline in patients with early-stage disease over 18 months. Donanemab helps reduce amyloid plaques in the brain, which is associated with slowing disease progression.

Read also: Pfizer Introduces Novel Myeloma Treatment in India for Patients with Limited Therapeutic Options

The significance of donanemab lies in its disease-modifying potential. Current treatments available in India, such as donepezil or memantine, primarily help manage symptoms by altering neurotransmitter activity, offering modest improvements in cognition but not slowing disease progression. Donanemab, by contrast, targets amyloid buildup directly, with clinical data suggesting it may slow cognitive decline if given early.

The Importance of Early Intervention

Early intervention is critical in treating Alzheimer's. Approximately one-third of patients in early symptomatic stages may progress rapidly, underscoring the importance of timely diagnosis and treatment. According to Rahul Kapur, senior director—medical at Lilly India, timely diagnosis and treatment can make a significant difference in the lives of patients.

India's Growing Alzheimer's Burden

Read also: Eli Lilly to Launch Alzheimer's Disease Therapy Lormalzi in India This Month

India faces a growing Alzheimer's burden, with an estimated 8.8 million people living with dementia. Cases are expected to nearly double to about 16.9 million by 2036. The disease already costs the economy over Rs. 28,000 crore annually, driven by long-term care needs and productivity loss. Alzheimer's is often diagnosed late in India, limiting the window in which disease-modifying treatments may be effective.

A New Treatment Paradigm

Lilly's therapy introduces a fundamentally different treatment paradigm—one that targets the root pathology of Alzheimer's rather than its symptoms. Its once-monthly dosing, potential for limited-duration treatment, and focus on early-stage patients distinguish it from conventional therapies. However, experts note that the real-world impact will depend on broader changes in the ecosystem, including improved diagnosis rates, specialist infrastructure, and affordability.

Note: The table compares the effectiveness and dosing frequency of donanemab with current treatments available in India, such as donepezil and memantine.